Published in Cancer on June 15, 2000
Cancer vaccines and carbohydrate epitopes. Vaccine (2011) 1.40
Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol (2004) 1.16
Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol (2002) 0.91
Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy. Clin Exp Immunol (2012) 0.84
O-acetylation of GD3: an enigmatic modification regulating apoptosis? J Exp Med (2002) 0.83
Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity. Proc Natl Acad Sci U S A (2016) 0.75
Bio-recognition and functional lipidomics by glycosphingolipid transfer technology. Proc Jpn Acad Ser B Phys Biol Sci (2013) 0.75
Neogenin, Defined as a GD3-associated Molecule by Enzyme-mediated Activation of Radical Sources, Confers Malignant Properties via Intracytoplasmic Domain in Melanoma Cells. J Biol Chem (2016) 0.75
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
Absence of p350 subunit of DNA-activated protein kinase from a radiosensitive human cell line. Science (1995) 4.19
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 2.68
Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol (1999) 2.50
Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature (1980) 2.30
Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum (1984) 2.17
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
Studies on repair of adenovirus 2 by human fibroblasts using normal, xeroderma pigmentosum, and xeroderma pigmentosum heterozygous strains. Cancer Res (1974) 1.94
Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Clin Invest (1998) 1.85
Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res (1989) 1.84
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res (1994) 1.76
Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol (1986) 1.74
Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer (2005) 1.69
A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol (1994) 1.64
Isolation of two cell lines from a human malignant glioma specimen differing in sensitivity to radiation and chemotherapeutic drugs. Radiat Res (1993) 1.64
Tumor-infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. Gastroenterology (1990) 1.63
Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol (1999) 1.60
Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58
TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene (2009) 1.52
High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst (1990) 1.51
A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Methods (2007) 1.49
Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol (1999) 1.48
Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res (1996) 1.46
Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res (1990) 1.45
Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer (1992) 1.45
Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res (1999) 1.44
Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods (1992) 1.44
Brain tumor volume measurement: comparison of manual and semiautomated methods. Radiology (1999) 1.42
Gene amplification and gene dosage in cell lines derived from squamous cell carcinoma of the head and neck. Genes Chromosomes Cancer (1991) 1.42
Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res (1986) 1.38
Mesosomes: membranous bacterial organelles. Bacteriol Rev (1975) 1.35
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer (2013) 1.34
Base analog and neighboring base effects on substrate specificity of recombinant human G:T mismatch-specific thymine DNA-glycosylase. Biochemistry (1996) 1.32
Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res (2001) 1.32
Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther (1996) 1.31
Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res (2000) 1.30
SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene (2007) 1.29
Identification of seven differentially displayed transcripts in human primary and matched metastatic head and neck squamous cell carcinoma cell lines: implications in metastasis and/or radiation response. Oral Oncol (1997) 1.29
Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med (2001) 1.26
Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology (1997) 1.24
Chromosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromosomes Cancer (1990) 1.24
Correlation of B-FABP and GFAP expression in malignant glioma. Oncogene (1998) 1.23
Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods (1992) 1.22
Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest (1998) 1.22
Activation of Raf by ionizing radiation. Nature (1996) 1.22
The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer (2001) 1.22
Abnormalities of T lymphocyte subsets in patients with progressive systemic sclerosis (PSS, scleroderma). J Lab Clin Med (1981) 1.21
Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv Otorhinolaryngol (2005) 1.21
Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation. J Natl Cancer Inst (1991) 1.20
Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1. Br J Cancer (2000) 1.20
Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol (2000) 1.20
Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol (1987) 1.19
Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system? Br J Cancer (2005) 1.17
A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res (1996) 1.17
Repair of O6-methylguanine in DNA by demethylation is lacking in Mer- human tumor cell strains. Carcinogenesis (1983) 1.17
Clinical significance of decreased zeta chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res (1999) 1.17
Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res (2000) 1.16
Use of antibody to membrane adenosine triphosphatase in the study of bacterial relatioships. J Bacteriol (1971) 1.13
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ (2009) 1.13
Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood (1998) 1.13
IgA-containing circulating immune complexes in patients with igA nephropathy. Am J Med (1983) 1.12
Lymphocyte subpopulations at the site of "piecemeal" necrosis in end stage chronic liver diseases and rejecting liver allografts in cyclosporine-treated patients. Lab Invest (1984) 1.12
Immunologic analysis of mononuclear cells in liver tissues and blood of patients with primary sclerosing cholangitis. Hepatology (1985) 1.12
A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res (1988) 1.10
T-lymphocyte subsets in liver tissues of patients with primary biliary cirrhosis (PBC), patients with primary sclerosing cholangitis (PSC), and normal controls. J Clin Immunol (1984) 1.10
Lack of correlation between DNA-dependent protein kinase activity and tumor cell radiosensitivity. Cancer Res (1995) 1.10
Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res (2000) 1.10
Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate (2000) 1.09
Repair by human cells of adenovirus-2 damaged by psoralen plus near ultraviolet light treatment. Mutat Res (1975) 1.09
Ultraviolet sensitivity of Haemophilus influenzae transforming DNA. I. Effects of genetic mismatch and target size. Mutat Res (1971) 1.09
Isolation, phenotyping, and functional analysis of lymphocytes from human liver. Clin Immunol Immunopathol (1990) 1.09
The presence of IgE on the surface of lymphocytes in nasal polyps. J Allergy Clin Immunol (1975) 1.09
Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells. Cell Immunol (1991) 1.09
Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol (2014) 1.08
T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin Immunol Immunopathol (1993) 1.07
UV-induced alleviation of K-specific restriction of bacteriophage lambda. J Virol (1977) 1.07
Cytokines, immunoglobulins, and bacterial pathogens in middle ear effusions. Arch Otolaryngol Head Neck Surg (1995) 1.07
Cellular reactivation of ultraviolet-irradiated human adenovirus 2 in normal and xeroderma pigmentosum fibroblasts. Photochem Photobiol (1974) 1.05
Caspase-mediated degradation of T-cell receptor zeta-chain. Cancer Res (1999) 1.05
Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients. J Immunol Methods (1986) 1.05
Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues. Anal Biochem (1997) 1.04
Mechanisms responsible for signaling and functional defects. J Immunother (1998) 1.04
Radiation-induced DNA damage and repair in cells of a radiosensitive human malignant glioma cell line. Radiat Res (1995) 1.04
The in vivo effect of hepatotrophic factors augmenter of liver regeneration, hepatocyte growth factor, and insulin-like growth factor-II on liver natural killer cell functions. Hepatology (1997) 1.04
Immune system differences in men with hypo- or hypercholesterolemia. Clin Immunol Immunopathol (1997) 1.03
Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res (1999) 1.03
Tissue distribution of human NK cells studied with anti-Leu-7 monoclonal antibody. J Immunol (1983) 1.02
Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood (2000) 1.02
Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2. Cancer (1989) 1.02
Immunodiagnosis of mesothelioma: use of antimesothelial cell serum in an indirect immunofluorescence assay. Cancer (1979) 1.02
Quantitation of red cell porphyrins by fluorescence scanning after thin-layer chromatography. Clin Chim Acta (1978) 1.01
Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic. Cell Immunol (1993) 1.01
Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res (1996) 1.01
Natural killer activity of human liver-derived lymphocytes in various liver diseases. Hepatology (1991) 1.01
Infection of UV-irradiated xeroderma pigmentosum fibroblasts by herpes simplex virus: study of capacity and Weigle reactivation. Mutat Res (1976) 1.01
Analysis of intestinal lymphocyte subpopulations in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Am J Clin Pathol (1987) 1.00
The diagnostic value of blood plasma porphyrin methyl ester profiles produced by quantitative TLC. Int J Biochem (1978) 1.00
Competition of peptide-MHC class I tetrameric complexes with anti-CD3 provides evidence for specificity of peptide binding to the TCR complex. Cytometry (2000) 1.00